Top

Published in:

Open Access 01-08-2023 | Triage | Research

Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors

Authors: André Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, Stellio Giacomini, Sébastien Bugeia, Garance Gutknecht, Gilliosa Spurrier-Bernard, Veronica Aedo-Lopez, Nuria Mederos, Sofiya Latifyan, Alfredo Addedo, Olivier Michielin, Manuela Eicher

Published in: Supportive Care in Cancer | Issue 8/2023

Abstract

Purpose

The use of electronic patient-reported outcome (ePRO) data in routine care has been tied to direct patient benefits such as improved quality of care and symptom control and even overall survival. The modes of action behind such benefits are seldom described in detail. Here, we describe the development of a model of care leveraging ePRO data to monitor and manage symptoms of patients treated with immune checkpoint inhibitors.

Methods

Development was split into four stages: (1) identification of an underlying theoretical framework, (2) the selection of an ePRO measure (ePROM), (3) the adaptation of an electronic application to collect ePRO data, and (4) the description of an ePRO-oriented workflow. The model of care is currently evaluated in a bicentric longitudinal randomized controlled phase II trial, the IePRO study.

Results

The IePRO model of care is grounded in the eHealth Enhanced Chronic Care Model. Patients are prompted to report symptoms using an electronic mobile application. Triage nurses are alerted, review the reported symptoms, and contact patients in case of a new or worsening symptom. Nurses use the UKONS 24-hour telephone triage tool to issue patient management recommendations to the oncology team. Adapted care coordinating procedures facilitate team collaboration and provide patients with timely feedback.

Conclusion

This report clarifies how components of care are created and modified to leverage ePRO to enhance care. The model describes a workflow that enables care teams to be proactive and provide patients with timely, multidisciplinary support to manage symptoms.

Available only for authorised users

Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers 12:738. https://doi.org/10.3390/cancers12030738CrossRefPubMedPubMedCentral

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073–4126. https://doi.org/10.1200/JCO.21.01440CrossRefPubMed

Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primer 6:38. https://doi.org/10.1038/s41572-020-0160-6CrossRef

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2017;28:iv119–42. https://doi.org/10.1093/annonc/mdx225

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356. https://doi.org/10.1056/NEJMoa1709684CrossRefPubMedPubMedCentral

Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S et al (2021) Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 32:917–925. https://doi.org/10.1016/j.annonc.2021.03.204CrossRefPubMed

Tang S-Q, Tang L-L, Mao Y-P, Li W-F, Chen L, Zhang Y et al (2021) The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res Treat 53:339–354. https://doi.org/10.4143/crt.2020.790CrossRefPubMed

Johnson DB, Nebhan CA, Moslehi JJ, Balko JM (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19:254–267. https://doi.org/10.1038/s41571-022-00600-wCrossRefPubMedPubMedCentral

Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO et al (2020) Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor–associated myocarditis. Circulation 141:2031–2034. https://doi.org/10.1161/CIRCULATIONAHA.119.044703CrossRefPubMedPubMedCentral

10.

Plaçais L, Michot J-M, Champiat S, Romano-Martin P, Baldini C, Joao MS et al (2021) Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. Brain Commun 3:fcab220. https://doi.org/10.1093/braincomms/fcab220CrossRefPubMedPubMedCentral

11.

Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27:559–574. https://doi.org/10.1093/annonc/mdv623CrossRefPubMed

12.

Naing A, Hajjar J, Gulley JL, Atkins MB, Ciliberto G, Meric-Bernstam F et al (2020) Strategies for improving the management of immune-related adverse events. J Immunother Cancer 8:e001754. https://doi.org/10.1136/jitc-2020-001754CrossRefPubMedPubMedCentral

13.

Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D et al (2022) The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline. Ann Oncol:S0923753422006913. https://doi.org/10.1016/j.annonc.2022.04.007

14.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36:1714–1768. https://doi.org/10.1200/JCO.2017.77.6385CrossRefPubMed

15.

Hoffner MSN, ANP-BC, AOCNP B, M. Rubin, MS, FNP-BC K. (2019) Meeting the challenge of immune-related adverse events with optimized telephone triage and dedicated oncology acute care. J Adv Pract Oncol:10. https://doi.org/10.6004/jadpro.2019.10.2.10

16.

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-019-0218-0

17.

Cheema PK, Iafolla MAJ, Nematollahi M, Berco F, Kaushik D, Matthews P et al (2022) A guide to implementing immune checkpoint inhibitors within a cancer program: experience from a large Canadian community centre. Curr Oncol 29:869–880. https://doi.org/10.3390/curroncol29020074CrossRefPubMedPubMedCentral

18.

Mendoza T (2018) Understanding the toxicity of cancer immunotherapies: use of patient-reported outcomes. J Immunother Precis Oncol 1:38. https://doi.org/10.4103/JIPO.JIPO_10_18CrossRef

19.

Zhang L, Zhang X, Shen L, Zhu D, Ma S, Cong L (2022) Efficiency of electronic health record assessment of patient-reported outcomes after cancer immunotherapy: a randomized clinical trial. JAMA Netw Open 5:e224427. https://doi.org/10.1001/jamanetworkopen.2022.4427CrossRefPubMedPubMedCentral

20.

Field J, Holmes MM, Newell D (2019) PROMs data: can it be used to make decisions for individual patients? A narrative review. Patient Relat Outcome Meas 10:233–241. https://doi.org/10.2147/PROM.S156291CrossRefPubMedPubMedCentral

21.

Basch E, Stover AM, Schrag D, Chung A, Jansen J, Henson S et al (2020) Clinical utility and user perceptions of a digital system for electronic patient-reported symptom monitoring during routine cancer care: findings from the PRO-TECT trial. JCO Clin Cancer Inform:947–957. https://doi.org/10.1200/CCI.20.00081

22.

Absolom K, Gibson A, Velikova G (2019) Engaging patients and clinicians in online reporting of adverse effects during chemotherapy for cancer: the eRAPID system electronic patient self-reporting of adverse events. Med Care 57:S59–S65. https://doi.org/10.1097/MLR.0000000000001085CrossRefPubMed

23.

Coolbrandt A, Van den Heede K, Vanhove E, De Bom A, Milisen K, Wildiers H (2011) Immediate versus delayed self-reporting of symptoms and side effects during chemotherapy: does timing matter? Eur J Oncol Nurs 15:130–136. https://doi.org/10.1016/j.ejon.2010.06.010CrossRefPubMed

24.

Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S et al (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 32:1480–1501. https://doi.org/10.1200/JCO.2013.53.5948CrossRefPubMed

25.

Leppla L, Schmid A, Valenta S, Mielke J, Beckmann S, Ribaut J et al (2021) Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth—the SMILe study. Support Care Cancer 29:8045–8057. https://doi.org/10.1007/s00520-021-06328-0CrossRefPubMedPubMedCentral

26.

Colomer-Lahiguera S, Bryant-Lukosius D, Rietkoetter S, Martelli L, Ribi K, Fitzpatrick-Lewis D et al (2020) Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review. J Patient-Rep Outcomes:4. https://doi.org/10.1186/s41687-020-00210-z

27.

Gee PM, Greenwood DA, Paterniti DA, Ward D, Miller LMS (2015) The eHealth Enhanced Chronic Care Model: a theory derivation approach. J Med Internet Res 17:e86. https://doi.org/10.2196/jmir.4067CrossRefPubMedPubMedCentral

28.

Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA 2002;288:1775–9. https://doi.org/10.1001/jama.288.14.1775.

29.

Bodenheimer T, Wagner EH, Grumbach K (2002) Improving primary care for patients with chronic illness - the chronic care model, part 2. JAMA 288:1909–1914. https://doi.org/10.1001/jama.288.15.1909CrossRefPubMed

30.

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC et al (2014) Development of the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JNCI. J Natl Cancer Inst 106:dju244–dju244. https://doi.org/10.1093/jnci/dju244

31.

Da Silva Lopes AM, Colomer-Lahiguera S, Mederos Alfonso N, Aedo-Lopez V, Spurrier-Bernard G, Tolstrup LK et al (2021) Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: a Delphi study. Eur J Cancer 157:225–237. https://doi.org/10.1016/j.ejca.2021.08.026CrossRefPubMed

32.

Wagner EH, Davis C, Homer CJ, Hagedorn SD, Austin B (2002) Abbi Kaplan. Curing the system - stories of change in chronic illness care, National Coalition on Health Care and the Institute for Healthcare Improvement

33.

Iivanainen S, Alanko T, Peltola K, Konkola T, Ekström J, Virtanen H et al (2019) ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study. J Cancer Res Clin Oncol 145:765–774. https://doi.org/10.1007/s00432-018-02835-6CrossRefPubMedPubMedCentral

34.

Schmalz O, Jacob C, Ammann J, Liss B, Iivanainen S, Kammermann M et al (2020) Digital monitoring and management of patients with advanced or metastatic non-small cell lung cancer treated with cancer immunotherapy and its impact on quality of clinical care: interview and survey study among health care professionals and patients. J Med Internet Res 22:e18655. https://doi.org/10.2196/18655CrossRefPubMedPubMedCentral

35.

Warrington L, Absolom K, Conner M, Kellar I, Clayton B, Ayres M et al (2019) Electronic systems for patients to report and manage side effects of cancer treatment: systematic review. J Med Internet Res 21:e10875. https://doi.org/10.2196/10875CrossRefPubMedPubMedCentral

36.

Hoffman AJ (2013) Enhancing self-efficacy for optimized patient outcomes through the theory of symptom self-management. Cancer Nurs 36:E16–E26. https://doi.org/10.1097/NCC.0b013e31824a730aCrossRefPubMedPubMedCentral

37.

Wendy H (2021) Oldenmenger, Corina J. G. van der Hurk, Doris Howell. Utilizing technology to manage symptoms. In: Charalambous A (ed) Dev. Util. Digit. Technol. Healthc. Assess. Monit. Springer, Cham, pp 55–72

38.

Girgis A, Durcinoska I, Levesque JV, Gerges M, Sandell T, Arnold A et al (2017) eHealth system for collecting and utilizing patient reported outcome measures for personalized treatment and care (PROMPT-Care) among cancer patients: mixed methods approach to evaluate feasibility and acceptability. J Med Internet Res 19:e330. https://doi.org/10.2196/jmir.8360CrossRefPubMedPubMedCentral

39.

Baeksted C, Pappot H, Nissen A, Hjollund NH, Mitchell SA, Basch E et al (2017) Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients. J Patient-Rep Outcomes 1:1. https://doi.org/10.1186/s41687-017-0005-6CrossRefPubMedPubMedCentral

40.

UKONS 24 hour triage rapid assessment and access toolkit. 2nd United Kingdom Oncology Nursing Society; 2016.

41.

Zhou L, Bao J, Setiawan IMA, Saptono A, Parmanto B (2019) The mHealth app usability questionnaire (MAUQ): development and validation study. JMIR MHealth UHealth 7:e11500. https://doi.org/10.2196/11500CrossRefPubMedPubMedCentral

42.

Sekhon M, Cartwright M, Francis JJ (2017) Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res:17. https://doi.org/10.1186/s12913-017-2031-8

43.

CFIR research team - center for clinical management research (2020) CFIR Interview Guide Tool. Consol Framew Implement Res. https://cfirguide.org/guide/app/#/. Accessed 8 Feb 2021

44.

Bryant AL, Coffman E, Phillips B, Tan X, Bullard E, Hirschey R et al (2020) Pilot randomized trial of an electronic symptom monitoring and reporting intervention for hospitalized adults undergoing hematopoietic stem cell transplantation. Support Care Cancer 28:1223–1231. https://doi.org/10.1007/s00520-019-04932-9CrossRefPubMed

45.

Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34:557–565. https://doi.org/10.1200/JCO.2015.63.0830CrossRefPubMed

46.

McCann L, Ream E, Armes J, Harris J, Kotronoulas G, Miaskowski C et al (2018) Remote monitoring systems in the cancer setting: eSMART: electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology for patients with cancer. The Breast 41:S4–S5. https://doi.org/10.1016/j.breast.2018.08.017CrossRef

47.

Mir O, Ferrua M, Fourcade A, Mathivon D, Duflot-Boukobza A, Dumont S et al (2022) Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med 28:1224–1231. https://doi.org/10.1038/s41591-022-01788-1CrossRefPubMed

48.

Basch E, Barbera L, Kerrigan CL, Velikova G (2018) Implementation of patient-reported outcomes in routine medical care. Am Soc Clin Oncol Educ Book:122–134. https://doi.org/10.1200/EDBK_200383

Title: Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors
Authors: André Manuel da Silva Lopes
Sara Colomer-Lahiguera
Célia Darnac
Stellio Giacomini
Sébastien Bugeia
Garance Gutknecht
Gilliosa Spurrier-Bernard
Veronica Aedo-Lopez
Nuria Mederos
Sofiya Latifyan
Alfredo Addedo
Olivier Michielin
Manuela Eicher
Publication date: 01-08-2023
Publisher: Springer Berlin Heidelberg
Keywords: Triage
Care
Checkpoint Inhibitors
Published in: Supportive Care in Cancer / Issue 8/2023
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-023-07934-w

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

Perioperative chemo outplays neoadjuvant CRT in esophageal cancer

05-06-2024 Esophageal Cancer News

LAURA heralds practice change for locally advanced NSCLC

03-06-2024 NSCLC News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2023

Oncologists’ responsibility, comfort, and knowledge managing hyperglycemia in patients with cancer undergoing chemotherapy: a cross sectional study

Sociocultural factors associated with physical activity in Black prostate cancer survivors

Reply to: “Predictors of psychoneurological symptoms in cancer caregivers over time: role of caregiving burden, stress, and patient symptoms”

Effects of music-based interventions on cancer-related pain, fatigue, and distress: an overview of systematic reviews

Implementing a cognitive behavioral intervention for patients with head and neck cancer

Comorbidity burden and health-related quality of life in men with advanced prostate cancer